Company profile for HDT Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

HDT Bio Corp. is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. HDT Bio, was launched in 2018 after 25 years of success within infectious disease research and development from the Infectious Disease Research Institute (IDRI). IDRI has ga...
HDT Bio Corp. is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. HDT Bio, was launched in 2018 after 25 years of success within infectious disease research and development from the Infectious Disease Research Institute (IDRI). IDRI has gained a reputation as being one of the few institutions worldwide that has the capacity to take an idea for a global health solution from the very early stages of basic research all the way through commercialization.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1616 Eastlake Ave E #280, Seattle, WA 98102
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/fda-greenlights-hdt-bios-first-in-class-hdt-321-for-the-prevention-of-deadly-tick-borne-disease-302561734.html

PR NEWSWIRE
19 Sep 2025

https://www.prnewswire.com/news-releases/malarvx-licenses-hdt-bios-reprnalion-technology-for-novel-malaria-vaccine-302353757.html

PR NEWSWIRE
16 Jan 2025

https://www.prnewswire.com/news-releases/hdt-bio-to-help-spearhead-rna-vaccine-development-in-national-pandemic-preparedness-initiative-302250815.html

PR NEWSWIRE
17 Sep 2024

https://www.prnewswire.com/news-releases/hdt-bio-publishes-peer-reviewed-article-describing-the-development-of-an-rna-vaccine-to-prevent-infection-and-disease-caused-by-enterovirus-d68-302217086.html

PR NEWSWIRE
07 Aug 2024

https://www.moneycontrol.com/news/business/emcure-gennova-settle-litigation-with-hdt-ink-pact-to-develop-mrnavaccines-12730374.html

Viswanath Pilla MONEYCONROL
23 May 2024

https://www.prnewswire.com/news-releases/hdt-bio-receives-749-000-ezbaa-contract-and-partners-with-barda-under-project-nextgens-enablers-program-302039657.html

PR NEWSWIRE
23 Jan 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty